CD33

Across TCGA pan-cancer cohorts, CD33 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of CD33’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CD33 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CD33 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

KIRC, THCA, and LUAD are the cancer types where CD33 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD33 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+1.267	<.001	12	view →
THCA	Male	II,III,IV	+0.645	<.001	10	view →
LUAD	Male	II,III,IV	−1.337	<.001	9	view →
KIRP	Male	All	+1.125	<.001	9	view →
LUSC	Male	II,III,IV	−1.848	<.001	8	view →
COAD	All	All	−0.456	<.001	8	view →
HNSC	Female	II,III,IV	+0.436	.003	6	view →
BLCA	Male	III,IV	−0.564	.006	5	view →
KICH	All	II,III,IV	−0.415	.005	4	view →
PAAD	All	All	−1.467	.012	2	view →
CHOL	All	II,III,IV	−0.584	.026	2	view →
UCEC	All	All	−0.426	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

CD33–KIRC

Open the KIRC breakdown →